you are probably right that the management knows better because the FDA may have a bunch of other issues it can pick on MNKD even if it overlooks the bioequivalence thing.

The point is probably that Al thinks he can get through this difficult stage and the company wasn't pushed to the brink of failure like MELA and OREX.